Dermatose Degenerativa Induzida por D-penicilamina em Paciente com Doença de Wilson

Rui Pedro Santos¹, Joana Gomes², Celeste Brito²
¹Internista de Dermatovenereologia/Resident, Dermatovenereology, Hospital de Braga, Braga, Portugal
²Especialista de Dermatovenereologia/Specialist of Dermatovenereology, Hospital de Braga, Braga, Portugal

RESUMO – As dermatoses degenerativas induzidas por D-penicilamina incluem, entre outras, a elastose perfurante serpiginosa e o pseudo-pseudoxantoma elástico. A elastose perfurante serpiginosa é uma doença perfurante rara caracterizada pela eliminação transepidérmica de fibras elásticas anormais. Esta condição pode ser idiopática, reativa ou induzida por D-penicilamina, habitualmente utilizada para o tratamento da doença de Wilson, cistinúria, artrite reumatóide ou esclerose sistémica. Manifestações cutâneas semelhantes a pseudoxantoma elástico mas sem história familiar e mutações do gene ABCC6 foram identificadas como sendo uma dermopatia induzida por D-penicilamina e designada de pseudo-pseudoxantoma elástico.

Descreve-se o caso de uma mulher de 17 anos tratada por vários anos com D-penicilamina para doença de Wilson, com pápulas assintomáticas, algumas cor de pele e hiperqueratóticas e outras macias e amareladas, na região cervical e face. A histopatologia mostrou a eliminação transepidérmica de fibras elásticas espessadas, em forma de dentes de serra. Estes achados sugeriram uma dermopatia induzida por D-penicilamina e os autores consideraram o diagnóstico de elastose perfurante serpiginosa e pseudo-pseudoxantoma elástico no mesmo paciente. O fármaco foi alterado para acetato de zinco sem lesões novas, mas com manutenção das lesões existentes no seguimento a 1 ano.

PALAVRAS-CHAVE – Penicilamina/efeitos adversos; Degeneração Hepatolenticular; Doenças da Pele/induzidas quimicamente; Pseudoxantoma Elástico.

D-Penicillamine Induced Degenerative Dermopathy in a Patient with Wilson Disease

ABSTRACT – D-penicillamine induced degenerative dermatosis include, among others, elastosis perforans serpiginosa, and pseudo-pseudoxanthoma elasticum. Elastosis perforans serpiginosa is a rare perforating disease characterized by transepidermal elimination of abnormal elastic fibers. This condition can be idiopathic, reactive or induced by D-penicillamine, commonly used for the treatment of Wilson disease, cystinuria, rheumatoid arthritis or systemic sclerosis. Cutaneous manifestations resembling pseudoxanthoma elasticum but lacking familiar history and ABCC6 mutations have been identified as a D-penicillamine induced dermopathy and called pseudo-pseudoxanthoma elasticum.

The authors present a 17-year-old caucasian female treated for several years with D-penicillamine for Wilson disease who developed asymptomatic papules, some hyperkeratotic skin-colored and other soft and yellowish, on the cervical region and face. Histopathology showed transepidermal elimination of numerous, branched, sawtooth-like elastic fibers. These findings suggested a D-penicillamine induced dermopathy and the authors considered the diagnosis of both elastosis perforans serpiginosa and pseudo-pseudoxanthoma elasticum in the same patient. The drug was switched to zinc acetate. No newer lesions appeared thereafter but previous lesions persisted at the 1 year follow-up.

KEYWORDS – Penicillamine/adverse effects; Hepatolenticular Degeneration; Pseudoxanthoma Elasticum; Skin Diseases/chemically induced.

Correspondência: Rui Pedro Santos
Serviço de Dermatologia
Hospital de Braga
Rua de Santa Bárbara nº52
4435-595 Baguim do Monte, Braga, Portugal
Email: drruisantos@hotmail.com
DOI: https://dx.doi.org/10.29021/spdv.76.2.826

Recebido/Received
12 Outubro/October 2017
Aceite/Accepted
08 Março/March 2018
INTRODUCTION

D-penicillamine induced degenerative dermatosis includes elastosis perforans serpiginosa (EPS), pseudoxanthoma elasticum-like skin changes or pseudo-pseudoxanthoma elasticum (PPXE), acquired cutis laxa and anetoderma.1 Elastosis perforans serpiginosa is a rare perforating disease characterized by transepidermal elimination of abnormal elastic fibers. This condition is typically found in adolescents and young adults with a male preponderance.2 EPS has been classified as idiopathic, reactive or drug-induced.3-5 It is usually an isolated condition but has also been associated with other diseases like Down’s syndrome, Marfan syndrome, morphea, systemic sclerosis, cutis laxa and pseudoxanthoma elasticum (PXE).6 The only drug known to induce EPS is D-penicillamine, a heavy metal chelator still commonly used in the treatment of Wilson disease (WD), cystinuria, rheumatoid arthritis or systemic sclerosis.1,7

Pseudoxanthoma elasticum is an autosomal recessive disorder characterized by progressive mineralization and fragmentation of elastic fibers in various systems: skin (yellowish papules, “cobblestoning,” and redundant folds in flexural areas), eyes (angioid streaks and retinal defects) and cardiovascular system (renovascular hypertension, angina pectoris, myocardial infarction, and stroke).8 Cutaneous manifestations resembling PXE without familiar history and ABCC6 mutations have been identified as a D-penicillamine induced dermatopathy. These pseudoxanthoma elasticum-like skin changes are also known as pseudo-pseudoxanthoma elasticum.

The authors present a case of a D-penicillamine induced dermatopathy in a young adult female with WD treated for several years with D-penicillamine, that poses a difficult distinction between EPS and PPXE and is probably an association of both entities.

CASE PRESENTATION

A 17-year-old caucasian female patient affected with WD from the age of 5 and treated since then with D-penicillamine at daily doses ranging from 900 mg to 4 g. There were no hepatic or neurologic manifestations of WD. There was no relevant family history.

The patient was presented to our Dermatology department with a one year history of multiple, progressively appearing, asymptomatic papules located in the cervical region.

The clinical observation revealed multiple discrete, small, skin-colored to yellowish papules, some hyperkeratotic, others soft to palpation, distributed through the neck and in a smaller number, on the face (Fig 1). In addition, there was an atrophic lesion with a poorly defined arciform border and telangiectasia of about 1.5 cm located on the right cervical area (Fig. 2). No lesions were seen in other locations.

The patient was previously treated topically for acne vulgaris without any improvement.

Histopathology from an incisional skin biopsy on the cervical plaque revealed an acanthotic, hyperkeratotic epidermis; transepidermal elimination of numerous, branched, sawtooth-like elastic fibers; a mixed dermal inflammatory infiltrate and some multinucleated giant cells (Fig.s 3-4). These findings suggested a D-penicillamine induced dermatopathy. From the clinico-pathological correlation a diagnosis of penicillamine-induced dermatosis consisting of mixed findings of EPS and PPXE was made.

Echocardiogram and ECG were normal. No other exams were performed due to the lack of symptomatic complaints or clinical findings.

D-penicillamine was switched to zinc acetate 50 mg 3 id with good control of WD.

At 1 year follow-up, however, cutaneous lesions still persist but no newer papules appeared.

DISCUSSION

Wilson disease is an autosomal recessive disorder caused by a mutation in the gene ATP7B that encodes a protein expressed on hepatocytes and involved in the excretion of copper into the bile.9 In WD copper is accumulated in the liver, brain and
abnormalities in elastic fibers similar to EPS and PPXE essentially by two mechanisms: 1) direct interference with tropocollagen cross-linking (this applies only to soluble collagen and not mature insoluble collagen which may explain why certain lesions take years to become apparent and others appear after the drug withdrawal); 2) inhibition of lysil oxidase, a copper dependent enzyme that catalyses the cross-linking of elastic and collagen fibers. These processes result in unstable elastic fibers that may be extruded in a foreign body reaction-like mechanism. This phenomenon can theoretically occur in any location with elastic fibers like the skin, lung, pharyngeal tissue, artery walls, joint capsules or cervical connective tissue.

Clinically EPS occurs as asymptomatic, erythematous to skin-colored, hyperkeratotic papules usually arranged in annular or serpiginous configuration that can occur anywhere on the body surface but are typically found in the neck and upper extremities. D-penicillamine induced EPS lesions are clinically indistinguishable from the idiopathic form of the disease.

Cutaneous findings of PPXE are clinically similar to those of PXE but there is neither a positive familiar history of the disease nor the presence of the mutations of the ABCC6 gene. Also, there is an important histological difference: in PPXE there is no evidence of calcium deposition on the dermal elastic fibers, which is a critical factor in the pathogenesis of the disease. PPXE findings include a “plucked-chicken skin” appearance on the neck and in the axillae with excessive wrinkling and elastotic papules and redundant skin folds in flexural areas. The typical yellow discoloration of the PPXE and PXE lesions is due to the presence of elevated quantities of abnormal dermal elastic fibers.

In the patient described there were some soft, yellowish papules similar to PPXE but other sites of involvement and redundant folds in flexural areas were lacking. Also, the “plucked-chicken skin” was not evident. On the other side, the hyperkeratotic skin-colored papules on the neck are suggestive of EPS. Although the traditional annular or serpiginous distribution was not present, there are reports of isolated papules on EPS cases. In our patient, we observed an atrophic plaque that may be a sequelar finding of an annular plaque. Before this, the authors considered that three diagnostic options were viable: atypical EPS, atypical PPXE or a combination of both. There are a few reports in the literature supporting this latter option.

The histopathology of these diseases are similar and usually show an acanthotic, hyperkeratotic epidermis with a mixed dermal inflammatory infiltrate and few giant cells. Atrophy of the skin can be found at the center of EPS lesions. Transdermal perforating channels extend from the dermis and contain a mixture of eosinophilic elastic fibers, basophilic debris and inflammatory cells. In drug induced EPS, elastic fiber stain shows thickened serrated morphology resulting in the typical “lumpy-bumpy” or “bramble-bush” pattern both in lesional and non-lesional skin.

EPS and PPXE lesions usually arise after several decades of D-penicillamine medication, have a chronic course and can even arise after drug withdrawal. Spontaneous resolution has been described several months after drug withdrawal. Although there is no effective treatment for D-penicillamine induced dermatopathies the best option seems drug suspension and

**Figure 3** - H&E 100x - Acanthotic epidermis and transepidermal elimination of elastic fibers. Mixed dermal inflammatory infiltrate.

**Figure 4** - Orcein staining of elastic fibers 100x - Transepidermal elimination of numerous, branched, sawtooth-like elastic fibers.

The current theory is that D-penicillamine induces eye damaging these organs and causing potentially threatening complications.

The D enantiomer of penicillamine is a well-known heavy metal chelator used as a therapeutic option in several different diseases like WD, cystinuria, rheumatoid arthritis or systemic sclerosis. Although the clinical outcome is good, D-penicillamine is known to cause many adverse effects, both cutaneous and extracutaneous. Approximately half the patients will have a side effect within the first 6 months and up to one-third will have to discontinue the drug. Cutaneous adverse effects are the most prevalent occurring in up to 50% of patients and leading to drug withdrawal in 10% of patients. There are four types of penicillamine-induced dermatosis: 1) acute hypersensitive reactions, including urticaria; 2) dermopathies characterized by elastic fibers abnormalities (like EPS and PPXE); 3) auto-immune disorders including bullous and connective tissue disorders and 4) miscellaneous dermatosis (lichen planus, psoriasisform dermatitis, alopecia and nail changes).

About 1% of the patients treated with penicillamine for decades will develop EPS.
switch to another medication of the underlying disease. For WD the main options are trientine or zinc, both with good results. In our patient the underlying WD remained well controlled with zinc acetate and no newer lesions appeared for one year. However, a few of the previously existing lesions remain.

In conclusion, we present this case of D-penicillamine induced dermatosis to illustrate the importance of recognition of these lesions, which may be subtle and usually asymptomatic and to highlight that due to the slow penicillamine metabolism, lesions can persist or even arise even after drug withdrawal. Although the association of true PXE and EPS is well recognized, the presence in the same patient of lesions clinically compatible with both EPS and PPXE induced by penicillamine is a rare event with few reports in the literature.

**Caso Clínico**


